Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

被引：0
|
作者：
Boehm, Michael [1 ]
Butler, J. [2 ]
Filippatos, G. [3 ]
Ferreira, J. P. [4 ]
Pocock, S. J. [5 ]
Abdin, A. [1 ]
Mahfoud, F. [1 ]
Brueckmann, M. [6 ]
Gollop, N. D. [6 ]
Iwata, T. [7 ]
Ponikowski, P. [8 ]
Wanner, C. [9 ]
Zannad, F. [4 ]
Packer, M. [10 ]
Anker, S. D. [11 ]
机构：
[1] Univ Hosp Saarland, Clin Internal Med 3, Cardiol Angiol & Intens Care Med, Homburg, Germany
[2] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA
[3] Natl & Kapodistrian Univ Athens, Med Sch, Athens, Greece
[4] Univ Lorraine, INSERM, Ctr Invest Clin Plurithemat, CICP 1433, Nancy, France
[5] London Sch Hyg & Trop Med, Dept Med Stat, London, England
[6] Boehringer Ingelheim Int, Ingelheim, Germany
[7] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[8] Wroclaw Med Univ, Wybrzeze L Pasteura 1, PL-50367 Wroclaw, Poland
[9] Univ Hosp Wurzburg, Wurzburg, Germany
[10] Baylor Univ, Med Ctr, Dallas, TX USA
[11] German Ctr Cardiovasc Res DZHK, Berlin Inst Hlth Ctr Regenerat Therapies, Dept Cardiol BCRT, Partner Site Berlin, Berlin, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：131 / 132
页数：2
相关论文
共 50 条
  • [41] PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) IN THE TREATMENT OF PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF) IN FRANCE, BASED ON EMPEROR-PRESERVED CLINICAL TRIAL
    Levy, P.
    Lamblin, N.
    Groyer, H.
    Chollet, J.
    Tardu, J.
    Linden, S.
    Fauchier, L.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S83 - S83
  • [42] Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'
    Kokhan, Elizaveta
    Kiyakbaev, Gayrat
    Medovchshikov, Vadim
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (07) : 1323 - 1324
  • [43] Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
    Takeuchi, Shinsuke
    Kohno, Takashi
    Goda, Ayumi
    Shiraishi, Yasuyuki
    Saji, Mike
    Nagatomo, Yuji
    Tanaka, Toshikazu D.
    Takei, Makoto
    Nakano, Shintaro
    Soejima, Kyoko
    Kohsaka, Shun
    Yoshikawa, Tsutomu
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 370 : 263 - 270
  • [44] Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial
    Sharma, Abhinav
    Ferreira, Joao Pedro
    Zannad, Faiez
    Pocock, Stuart J.
    Filippatos, Gerasimos
    Pfarr, Egon
    Petrini, Michaela
    Kraus, Bettina J.
    Wanner, Christoph
    Packer, Milton
    Butler, Javed
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, : 1337 - 1348
  • [45] Design of the EMPERIAL-preserved trial of empagliflozin in patients with chronic heart failure with preserved ejection fraction
    Ponikowski, P.
    Abraham, W. T.
    Lindenfeld, J.
    Zeller, C.
    Macesic, H.
    Brueckmann, M.
    Salsali, A.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 48 - 49
  • [46] Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos S.
    Jamal, Waheed
    Salsali, Afshin
    Schnee, Janet
    Kimura, Karen
    Zeller, Cordula
    George, Jyothis
    Brueckmann, Martina
    Zannad, Faiez
    Packer, Milton
    Packer, Milton
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos S.
    Zannad, Faiez
    George, Jyothis
    Brueckmann, Martina
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (10) : 1279 - 1287
  • [47] The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction
    Volpe, Massimo
    Patrono, Carlo
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (45) : 4621 - 4623
  • [48] Heart Failure and a Preserved Ejection Fraction A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials
    Packer, Milton
    Zannad, Faiez
    Anker, Stefan D.
    [J]. CIRCULATION, 2021, 144 (15) : 1193 - 1195
  • [49] Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
    Patel, Ravi B.
    Mehta, Rupal
    Redfield, Margaret M.
    Borlaug, Barry A.
    Hernandez, Adrian F.
    Shah, Sanjiv J.
    Dubin, Ruth F.
    [J]. JOURNAL OF CARDIAC FAILURE, 2020, 26 (03) : 233 - 242
  • [50] Empagliflozin benefits in patients with heart failure and preserved ejection fraction
    Anker, Stefan D.
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans Pieter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Esteban Gomez-Mesa, Juan
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Iwata, Tomoko
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    [J]. NATURE MEDICINE, 2022, 28 (12) : 2480 - 2481
12345